Waubant E, Banwell B, Wassmer E, Sormani M, Amato M, Hintzen R, Krupp L, Rostásy K, Tenembaum S, Chitnis T, Aaen G, Ben Adou E, Al-Roughani R, Alvarez V, Anagnostouli M, Anlar B, Armangue T, Arrambide G, Baroncini D, Bembeeva R, Benson L, Bizjak N, Blaschek A, Boyko A, Brenton J, Brück W, Klein da Costa B, Dive D, Elpers C, Filippi M, de Oliveira Fragomeni M, Havrdova E, Hemingway C, Kornek B, Deiva K, Lacy A, Liba Z, Lim M, Lotze T, Mah J, Makhani N, Mar S, McKay K, Menascu S, Moiola L, Mulero P, Ndiaye M, Neuteboom R, Ness J, Lobato de Oliveira E, Otallah S, Patti F, Albino da Paz J, Perez C, Pohl D, Ponsonby A, Rensel M, Rocca M, Rijke N, Rodriguez M, Rossman I, Sakuma H, Schreiner T, Schteinschnaider A, Sikes E, Simone I, Sweeney M, Tillema J, Troxell R, Verhelst H, Vilchez L, De Waele L, Weinstock-Guttman B, Wilbur C, Yann M, Yeh E, Zafeiriou D. Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG. Neurology 2019, 92: 10.1212/wnl.0000000000007572. PMID: 31043474, PMCID: PMC6556085, DOI: 10.1212/wnl.0000000000007572.Peer-Reviewed Original Research